Cancer-Breast-Neutropenia
| Title: | Randomized, OpEn-Label, Active-ContrOl Trial of SPI-2012 (Eflapegrastim) Versus Pegfilgrastim in the Management of Chemotherapy-Induced Neutropenia in Early-Stage Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) (RECOVER) |
| Description: | The purpose of this study is to compare the efficacy of SPI-2012 with pegfilgrastim in patients with early-stage breast cancer receiving docetaxel and cyclophosphamide (TC) to prevent and reduce Neutropenia that is associated with cancer chemotherapy. |
| Drug/Procedure: | SPI-2012; Pegfilgrastim; Docetaxel; Cyclophosphamide |
| NCT Number: | 02953340 |
| Notes: | Phase 3 |
| Start Date: | 9/14/17 |
| Status: | Recruiting |
| Principal Name: | Alan Langerak, MD |
| Contact Name: | Erin Hawks, CCRC |
| Phone: | (208)367-3481 |